Karyopharm Therapeutics
Thomas Nimmer, MBA, has extensive experience in quality assurance and compliance roles in various pharmaceutical companies. Thomas has managed GxP quality management systems, audits, and vendor quality risk management programs. Additionally, Thomas has led training and knowledge management initiatives, implemented new risk-based systems, and authored numerous controlled documents to facilitate quality processes. Thomas has a strong background in developing and implementing quality culture transformation programs and is skilled in leading cross-functional assessments and compliance education for global teams. Their expertise in GxP compliance, HA inspection management, and risk assessment has been integral to the success of the companies Thomas has worked for.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).